MCID: SLV012
MIFTS: 54

Salivary Gland Adenoid Cystic Carcinoma

Categories: Rare diseases, Cancer diseases, Endocrine diseases, Skin diseases, Oral diseases

Aliases & Classifications for Salivary Gland Adenoid Cystic Carcinoma

MalaCards integrated aliases for Salivary Gland Adenoid Cystic Carcinoma:

Name: Salivary Gland Adenoid Cystic Carcinoma 12 51 14
Adenoid Cystic Carcinoma 12 72 49 69
Cylindroma 12 49
Adenoid Cystic Carcinoma of Salivary Gland 69
Carcinoma, Adenoid Cystic 41
Eccrine Dermal Cylindroma 69
Carcinoma Adenoid Cystic 51
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 49
Carcinoma, Cribriform 69
Cribriform Carcinoma 49
Cylindroma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4866
MeSH 41 D003528
NCIt 46 C2970

Summaries for Salivary Gland Adenoid Cystic Carcinoma

NIH Rare Diseases : 49 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. Unfortunately, ACC is typically an aggressive form of cancer that has a poor long-term outlook. Last updated: 6/21/2017

MalaCards based summary : Salivary Gland Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma, is related to lung adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma, and has symptoms including pain An important gene associated with Salivary Gland Adenoid Cystic Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Doxepin and Histamine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, brain and lung, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and growth/size/body region

Disease Ontology : 12 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Wikipedia : 72 Adenoid cystic carcinoma (sometimes referred to as adenocyst, malignant cylindroma, adenocystic,... more...

Related Diseases for Salivary Gland Adenoid Cystic Carcinoma

Diseases related to Salivary Gland Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Related Disease Score Top Affiliating Genes
1 lung adenoid cystic carcinoma 33.4 HRAS KIT
2 polymorphous low-grade adenocarcinoma 30.3 CCND1 KIT MKI67
3 benign breast phyllodes tumor 30.1 KIT MKI67
4 adenocarcinoma 29.3 CCND1 CDH1 HRAS KIT
5 cervical adenoid cystic carcinoma 12.4
6 trachea adenoid cystic carcinoma 12.4
7 maxillary sinus adenoid cystic carcinoma 12.4
8 prostate adenoid cystic carcinoma 12.4
9 lacrimal gland adenoid cystic carcinoma 12.4
10 esophageal adenoid cystic carcinoma 12.4
11 breast adenoid cystic carcinoma 12.3
12 laryngeal adenoid cystic carcinoma 12.3
13 bartholin's gland adenoid cystic carcinoma 12.3
14 parotid gland adenoid cystic carcinoma 12.3
15 malignant cylindroma 12.3
16 cribriform carcinoma 12.3
17 ethmoid sinus adenoid cystic carcinoma 12.2
18 adnexal spiradenoma/cylindroma of a sweat gland 12.2
19 poncet-spiegler's cylindroma 12.2
20 adenoid cystic carcinoma of the corpus uteri 12.2
21 cutaneous adenocystic carcinoma 12.1
22 brooke-spiegler syndrome 12.0
23 cylindromatosis, familial 12.0
24 lymph node adenoid cystic carcinoma 11.1
25 adenoiditis 11.0
26 lymphoma, small cleaved-cell, diffuse 10.4 BCL2 CCND1
27 spiradenoma 10.4
28 extramedullary plasmacytoma 10.4 BCL2 CCND1
29 central pontine myelinolysis 10.4 AQP1 BCL2
30 pyosalpinx 10.3 KIT NOS2
31 pulmonary vein stenosis 10.3 KIT MKI67
32 bladder adenocarcinoma 10.2 MKI67 PCNA
33 testicular torsion 10.2 BCL2 PCNA
34 bowen's disease 10.2 MKI67 PCNA
35 endotheliitis 10.2
36 oral leukoplakia 10.2 MKI67 PCNA
37 suppressor of tumorigenicity 3 10.2 BCL2 PCNA
38 crohn's colitis 10.2 CDH1 NOS2
39 endometrial stromal sarcoma 10.2 CCND1 KIT PCNA
40 hidradenocarcinoma 10.1 BCL2 CCND1 MKI67
41 keratocystic odontogenic tumor 10.1 BCL2 CCND1 MKI67
42 inflammatory myofibroblastic tumor 10.1 CCND1 KIT MKI67
43 gastric lymphoma 10.1 BCL2 PCNA
44 adenosarcoma 10.1 KIT MKI67
45 squamous cell carcinoma of the larynx 10.1 BCL2 MKI67 PCNA
46 gastrointestinal stromal tumor 10.1 CCND1 KIT MKI67
47 squamous cell carcinoma of the oral tongue 10.1 CCND1 CDH1 MKI67
48 oral cancer 10.1 CCND1 CDH1 PCNA
49 prostatitis 10.0
50 choroiditis 10.0

Graphical network of the top 20 diseases related to Salivary Gland Adenoid Cystic Carcinoma:



Diseases related to Salivary Gland Adenoid Cystic Carcinoma

Symptoms & Phenotypes for Salivary Gland Adenoid Cystic Carcinoma

UMLS symptoms related to Salivary Gland Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CCND1 MKI67 PCNA

MGI Mouse Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.29 CDH1 CCND1 CTTN AQP1 BCL2 HRAS
2 endocrine/exocrine gland MP:0005379 10.26 CCND1 AQP1 BCL2 CDH1 HRAS CYLD
3 behavior/neurological MP:0005386 10.23 BCL2 CCND1 AQP1 EN1 HRAS CYLD
4 cardiovascular system MP:0005385 10.22 BCL2 CDH1 CCND1 AQP1 EN1 CTTN
5 cellular MP:0005384 10.21 BCL2 CDH1 CCND1 EN1 CTTN CYLD
6 hematopoietic system MP:0005397 10.19 BCL2 CCND1 AQP1 EN1 KIT CTTN
7 homeostasis/metabolism MP:0005376 10.18 BCL2 CDH1 CCND1 AQP1 EN1 HRAS
8 mortality/aging MP:0010768 10.18 BCL2 CDH1 CTTN CCND1 AQP1 EN1
9 immune system MP:0005387 10.16 BCL2 CDH1 CCND1 EN1 CTTN CYLD
10 digestive/alimentary MP:0005381 10.14 BCL2 CDH1 CCND1 KIT HRAS CYLD
11 integument MP:0010771 10.09 CDH1 CCND1 BCL2 HRAS CYLD KIT
12 craniofacial MP:0005382 10.02 BCL2 CCND1 HRAS NOS2 KIT RUNX3
13 neoplasm MP:0002006 9.91 BCL2 CDH1 CCND1 KIT HRAS CYLD
14 no phenotypic analysis MP:0003012 9.87 CDH1 CTTN HRAS KIT PCNA MKI67
15 reproductive system MP:0005389 9.81 BCL2 CDH1 CCND1 AQP1 EN1 KIT
16 normal MP:0002873 9.8 CDH1 CCND1 EN1 HRAS CYLD KIT
17 respiratory system MP:0005388 9.56 CCND1 AQP1 CTTN HRAS CYLD KIT
18 skeleton MP:0005390 9.17 AQP1 CCND1 EN1 HRAS NOS2 KIT

Drugs & Therapeutics for Salivary Gland Adenoid Cystic Carcinoma

Drugs for Salivary Gland Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
2
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
4
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
5
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
6
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
7
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
8 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
9
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
10 Liver Extracts Phase 3,Phase 2,Phase 1
11 Alkylating Agents Phase 3,Phase 2,Phase 1
12 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
13 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
14 Antidepressive Agents Phase 3
15 Antidepressive Agents, Tricyclic Phase 3
16 Histamine Antagonists Phase 3
17
Histamine Phosphate Phase 3 51-74-1 65513
18 Neurotransmitter Agents Phase 3,Not Applicable
19 Psychotropic Drugs Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Analgesics Phase 3
22 Analgesics, Opioid Phase 3
23 Anesthetics Phase 3
24 Anesthetics, General Phase 3
25 Anesthetics, Intravenous Phase 3
26 Central Nervous System Depressants Phase 3
27 Narcotics Phase 3
28 Peripheral Nervous System Agents Phase 3,Not Applicable
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
30 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
31 Mitomycins Phase 3
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
33 Porfiromycin Phase 3
34 Antifungal Agents Phase 2, Phase 3,Phase 1
35 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
36 Hormone Antagonists Phase 2, Phase 3
37 Hormones Phase 2, Phase 3,Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
39 Steroid Synthesis Inhibitors Phase 2, Phase 3
40 Autonomic Agents Phase 3,Not Applicable
41 Cholinergic Agents Phase 3,Not Applicable
42 Antineoplastic Agents, Hormonal Phase 3
43 Appetite Stimulants Phase 3
44 Central Nervous System Stimulants Phase 3,Not Applicable
45 Contraceptive Agents Phase 3
46 Contraceptives, Oral Phase 3
47
Megestrol Phase 3 3562-63-8 3080587 19090
48 Antimitotic Agents Phase 3,Phase 2,Phase 1
49 Cola Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
50
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 114)

# Name Status NCT ID Phase Drugs
1 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
4 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
5 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
6 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
7 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
8 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
9 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
10 Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Unknown status NCT00180921 Phase 2 Imatinib
11 Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Unknown status NCT01192087 Phase 1, Phase 2 Cetuximab
12 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
13 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
14 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
15 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
16 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
17 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
18 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
19 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
20 Study of RAD001 in Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2 RAD001
21 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
22 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00581360 Phase 2 doxorubicin and bortezomib
23 Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2 AG-013736 (AXITINIB)
24 Dovitinib in Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2 TKI258 (Dovitinib):
25 Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Completed NCT01524692 Phase 2 Dovitinib (TKI258)
26 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
27 Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck Completed NCT01065844 Phase 2 Nelfinavir
28 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
29 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
30 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
31 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
32 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
33 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
34 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
35 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
36 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
37 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
38 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
39 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
40 Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Recruiting NCT03087019 Phase 2 Pembrolizumab
41 Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Recruiting NCT02883374 Phase 2 Chidamide
42 Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma Recruiting NCT02859012 Phase 2 Axitinib
43 Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer Recruiting NCT03146650 Phase 2
44 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
45 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab
46 Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 Recruiting NCT02857712 Phase 2 Axitinib
47 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
48 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting NCT03422679 Phase 1, Phase 2 CB-103
49 A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages Recruiting NCT03274414 Phase 2 Cisplatin
50 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide

Search NIH Clinical Center for Salivary Gland Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Genetic Tests for Salivary Gland Adenoid Cystic Carcinoma

Anatomical Context for Salivary Gland Adenoid Cystic Carcinoma

MalaCards organs/tissues related to Salivary Gland Adenoid Cystic Carcinoma:

38
Salivary Gland, Brain, Lung, Lymph Node, Trachea, Eye, Uterus

Publications for Salivary Gland Adenoid Cystic Carcinoma

Articles related to Salivary Gland Adenoid Cystic Carcinoma:

(show top 50) (show all 67)
# Title Authors Year
1
Expression of PIM-1 in salivary gland adenoid cystic carcinoma: Association with tumor progression and patients' prognosis. ( 29399171 )
2018
2
MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. ( 28594149 )
2017
3
Correction: Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. ( 28642227 )
2017
4
Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern china: A 25-year retrospective study. ( 28151884 )
2017
5
Early stage minor salivary gland adenoid cystic carcinoma has favourable prognosis. ( 28600602 )
2017
6
Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma. ( 28230926 )
2017
7
Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776. ( 28228352 )
2017
8
Risk of Nodal Metastasis in Major Salivary Gland Adenoid Cystic Carcinoma. ( 28168897 )
2017
9
B7-H3 regulates migration and invasion in salivary gland adenoid cystic carcinoma via the JAK2/STAT3 signaling pathway. ( 28386362 )
2017
10
Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. ( 27000157 )
2016
11
Carcinoma-Associated Fibroblasts Lead the Invasion of Salivary Gland Adenoid Cystic Carcinoma Cells by Creating an Invasive Track. ( 26954362 )
2016
12
Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. ( 27212063 )
2016
13
Downregulation of nucleophosmin expression inhibited proliferation and induced apoptosis in salivary gland adenoid cystic carcinoma. ( 27501253 )
2016
14
Type III TGF-I^ receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-I_B signaling. ( 26531330 )
2016
15
PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma. ( 27648129 )
2016
16
Inhibitory effects of silibinin on proliferation and lung metastasis of human high metastasis cell line of salivary gland adenoid cystic carcinoma via autophagy induction. ( 27822066 )
2016
17
Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. ( 26631070 )
2016
18
Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. ( 26862087 )
2016
19
Role of hypoxia-inducible factor-1I+ and CD146 in epidermal growth factor receptor-mediated angiogenesis in salivary gland adenoid cystic carcinoma. ( 25997612 )
2015
20
Salivary gland adenoid cystic carcinoma. ( 26214665 )
2015
21
Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. ( 26405993 )
2015
22
MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. ( 26693056 )
2015
23
Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. ( 26175943 )
2015
24
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma. ( 24510998 )
2014
25
Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. ( 24493792 )
2014
26
High expression of SOX2 is associated with poor prognosis in patients with salivary gland adenoid cystic carcinoma. ( 24828201 )
2014
27
A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro. ( 25065562 )
2014
28
Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma. ( 25551195 )
2014
29
Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. ( 25520866 )
2014
30
19-year oncologic outcomes and the benefit of elective neck dissection in salivary gland adenoid cystic carcinoma. ( 24170702 )
2013
31
Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. ( 22580922 )
2012
32
Developmental transcription factor EN1--a novel biomarker in human salivary gland adenoid cystic carcinoma. ( 21800291 )
2012
33
High expression of the autophagy gene Beclin-1 is associated with favorable prognosis for salivary gland adenoid cystic carcinoma. ( 22712799 )
2012
34
Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. ( 22647764 )
2012
35
Metastatic pleural effusion: a rare presentation of salivary gland adenoid cystic carcinoma. ( 21545072 )
2011
36
Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. ( 21551254 )
2011
37
Maslinic acid induces apoptosis in salivary gland adenoid cystic carcinoma cells by Ca2+-evoked p38 signaling pathway. ( 21279332 )
2011
38
Unfavorable clinical implications for hypermethylation of RUNX3 in patients with salivary gland adenoid cystic carcinoma. ( 21567090 )
2011
39
Expression of the membrane-cytoskeletal linker Ezrin in salivary gland adenoid cystic carcinoma. ( 21550270 )
2011
40
Critical regions and spreading of runt-related transcription factor-3 C-phosphate-G (CpG) island methylation in human salivary gland adenoid cystic carcinoma. ( 21658745 )
2011
41
CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. ( 21692051 )
2011
42
[Evolution pattern of the Runx3 gene 5'-CpG island methylation in human salivary gland adenoid cystic carcinoma]. ( 21223798 )
2010
43
RNAi knockdown of C-erbB2 expression inhibits salivary gland adenoid cystic carcinoma SACC-83 cell growth in vitro. ( 23554633 )
2010
44
[RUNX3 expression and its methylation of 5'-CpG island in salivary gland adenoid cystic carcinoma cell lines ACC-2, ACC-3 and ACC-M]. ( 21223819 )
2010
45
[Effects of Ezrin gene on the proliferation and invasion activity of human salivary gland adenoid cystic carcinoma]. ( 19575999 )
2009
46
NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. ( 19317804 )
2009
47
Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. ( 19688981 )
2009
48
Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. ( 18844240 )
2009
49
Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. ( 19589718 )
2009
50
Survival from salivary glands adenoid cystic carcinoma in European populations. ( 19095489 )
2009

Variations for Salivary Gland Adenoid Cystic Carcinoma

ClinVar genetic disease variations for Salivary Gland Adenoid Cystic Carcinoma:

6 (show all 14)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
2 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
3 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
5 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
6 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh38 Chromosome 3, 179210192: 179210192
7 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
8 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
9 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286
10 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
11 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
12 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
13 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
14 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113

Cosmic variations for Salivary Gland Adenoid Cystic Carcinoma:

9 (show top 50) (show all 2141)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM51381 KIT salivary gland,face,carcinoma,adenoid cystic carcinoma c.2386A>G p.R796G 31
2 COSM1658882 ZNF507 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.34C>A p.P12T 30
3 COSM1659071 WASF2 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.15G>T p.T5T 30
4 COSM1658927 VWA8 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4027G>A p.E1343K 30
5 COSM1658946 VWA5B1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1486G>A p.V496I 30
6 COSM1658865 UNC80 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.305A>G p.Q102R 30
7 COSM1659017 UBTF salivary gland,NS,carcinoma,adenoid cystic carcinoma c.106A>T p.N36Y 30
8 COSM1659040 UBTF salivary gland,NS,carcinoma,adenoid cystic carcinoma c.100A>C p.M34L 30
9 COSM1659032 TXNRD3 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.412A>G p.K138E 30
10 COSM1659053 TSC1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.3280G>T p.E1094* 30
11 COSM1659031 TRPV5 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.554A>G p.H185R 30
12 COSM1658989 TP53BP1 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.3854C>G p.T1285S 30
13 COSM43614 TP53 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.854A>C p.E285A 30
14 COSM1659070 TOMM34 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.555T>A p.P185P 30
15 COSM1658929 TOM1L2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.259G>A p.V87I 30
16 COSM34221 TIE1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.2050G>C p.A684P 30
17 COSM1659046 THRA salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.1162C>T p.R388W 30
18 COSM1658909 TFAP2D salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1306C>T p.R436W 30
19 COSM1659024 TBC1D31 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.845T>A p.L282Q 30
20 COSM1658982 TANGO6 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.352G>C p.G118R 30
21 COSM1658994 SUPT5H salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1094G>T p.R365L 30
22 COSM1658977 STXBP3 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1275G>C p.R425S 30
23 COSM3863360 SPEN salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4207C>T p.R1403* 30
24 COSM1659068 SOX6 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.630T>C p.D210D 30
25 COSM1658954 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.2564G>A p.R855Q 30
26 COSM1659007 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.3476G>T p.R1159L 30
27 COSM1659023 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4582T>A p.S1528T 30
28 COSM1658912 SLC26A2 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.1474C>T p.R492W 30
29 COSM1659026 SLC26A11 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1196T>C p.F399S 30
30 COSM1659093 SLC25A13 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.888G>A p.L296L 30
31 COSM1658992 SLC15A5 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.925C>G p.L309V 30
32 COSM1658944 SIK2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1387G>A p.E463K 30
33 COSM110695 SF3B1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1874G>T p.R625L 30
34 COSM1658998 SF3B1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1873C>A p.R625S 30
35 COSM1024904 SEC23B salivary gland,NS,carcinoma,adenoid cystic carcinoma c.5C>T p.A2V 30
36 COSM1658857 SCN11A salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1207T>C p.Y403H 30
37 COSM1658966 SCN10A salivary gland,NS,carcinoma,adenoid cystic carcinoma c.599C>T p.A200V 30
38 COSM1659012 SACS salivary gland,NS,carcinoma,adenoid cystic carcinoma c.6353C>A p.S2118Y 30
39 COSM1224460 RYR1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.5885C>T p.A1962V 30
40 COSM34768 RPS6KB2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.986G>A p.R329Q 30
41 COSM1659122 RPRD1B salivary gland,NS,carcinoma,adenoid cystic carcinoma c.192T>C p.N64N 30
42 COSM1659033 RNF38 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.623A>G p.H208R 30
43 COSM1658907 RALGAPA1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1222G>A p.V408I 30
44 COSM13036 PTPN11 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1520C>A p.T507K 30
45 COSM1658974 PTBP3 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1081C>G p.L361V 30
46 COSM1658975 PRKD2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1126C>G p.L376V 30
47 COSM1658781 PRDM16 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.677-1G>T p.? 30
48 COSM1658856 PQLC2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.719A>C p.E240A 30
49 COSM1659034 POT1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.725A>G p.Y242C 30
50 COSM1658879 PORCN salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1073C>A p.T358N 30

Copy number variations for Salivary Gland Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss BAI2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3S2 Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRD1 Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7A Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss MLL2 Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA9 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma

Expression for Salivary Gland Adenoid Cystic Carcinoma

Search GEO for disease gene expression data for Salivary Gland Adenoid Cystic Carcinoma.

Pathways for Salivary Gland Adenoid Cystic Carcinoma

Pathways related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 BCL2 CCND1 CDH1 HRAS KIT PCNA
2
Show member pathways
12.43 BCL2 CCND1 CDH1 HRAS KIT
3
Show member pathways
12.38 BCL2 CCND1 HRAS NOS2
4
Show member pathways
12.36 BCL2 CCND1 HRAS PCNA
5
Show member pathways
12.25 BCL2 CCND1 HRAS NOS2
6 12.03 CCND1 CTTN PCNA
7 12.01 CCND1 CDH1 NOS2
8
Show member pathways
11.99 BCL2 HRAS KIT
9 11.97 BCL2 CCND1 CDH1
10 11.89 BCL2 CCND1 PCNA
11 11.84 AQP1 CCND1 NOS2
12 11.82 BCL2 CCND1 CDH1 HRAS KIT NOS2
13 11.81 BCL2 CCND1 HRAS
14 11.8 BCL2 CCND1 NOS2
15 11.75 BCL2 HRAS PCNA
16 11.7 BCL2 CCND1 HRAS
17 11.65 BCL2 CCND1 NOS2
18 11.55 BCL2 CCND1 KIT
19 11.5 CDH1 KIT RUNX3
20 11.47 CCND1 CDH1 HRAS
21 11.39 CCND1 CDH1 HRAS NOS2
22 11.32 BCL2 CCND1 NOS2
23 11.21 CCND1 CTTN NOS2
24 10.96 CCND1 HRAS
25 10.85 CCND1 CDH1 CTTN

GO Terms for Salivary Gland Adenoid Cystic Carcinoma

Cellular components related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cortical cytoskeleton GO:0030863 8.62 CTTN NOS2

Biological processes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.71 BCL2 HRAS MKI67 PCNA
2 negative regulation of neuron apoptotic process GO:0043524 9.63 BCL2 EN1 HRAS
3 response to drug GO:0042493 9.62 AQP1 BCL2 CCND1 CDH1
4 focal adhesion assembly GO:0048041 9.49 BCL2 CTTN
5 response to iron ion GO:0010039 9.48 BCL2 CCND1
6 melanocyte differentiation GO:0030318 9.43 BCL2 KIT
7 hemopoiesis GO:0030097 9.43 BCL2 KIT RUNX3
8 developmental pigmentation GO:0048066 9.37 BCL2 KIT
9 regulation of developmental pigmentation GO:0048070 9.16 BCL2 KIT
10 lymphoid progenitor cell differentiation GO:0002320 8.96 BCL2 KIT
11 pigmentation GO:0043473 8.8 BCL2 EN1 KIT

Molecular functions related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proline-rich region binding GO:0070064 8.62 CCND1 CYLD

Sources for Salivary Gland Adenoid Cystic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....